The 2009 earthquake, magnitude mb 4.8, in the Pantanal Wetlands, west-central Brazil.

The main goal of this paper is to characterize the Coxim earthquake occurred in June 15th, 2009 in the Pantanal Basin and to discuss the relationship between its faulting mechanism with the Transbrasiliano Lineament. The earthquake had maximum intensity MM V causing damage in farm houses and was felt in several cities located around, including Campo Grande and Goiânia. The event had an mb 4.8 magnitude and depth was 6 km, i.e., it occurred in the upper crust, within the basement and 5 km below the Cenozoic sedimentary cover. The mechanism, a thrust fault mechanism with lateral motion, was obtained by P-wave first-motion polarities and confirmed by regional waveform modelling. The two nodal planes have orientations (strike/dip) of 300°/55° and 180°/55° and the orientation of the P-axis is approximately NE-SW. The results are similar to the Pantanal earthquake of 1964 with mb 5.4 and NE-SW compressional axis. Both events show that Pantanal Basin is a seismically active area, under compressional stress. The focal mechanism of the 1964 and 2009 events have no nodal plane that could be directly associated with the main SW-NE trending Transbrasiliano system indicating that a direct link of the Transbrasiliano with the seismicity in the Pantanal Basin is improbable.

Serum sickness-like reactions in patients receiving intravenous infliximab.

Infliximab, a monoclonal antibody against tumor necrosis factor (TNF) has been used successfully for the treatment of certain forms of Crohn's disease and rheumatoid arthritis. Both acute and delayed hypersensitivity reactions have been associated with the intravenous use of this drug. The delayed forms may present as a serum sickness-like illness and recognition of the clinical manifestations becomes crucial for early diagnosis and treatment. With the dramatic increase in the use of infliximab, there will likely be increased numbers of patients with this type of reaction. These patients may have received this drug days or even weeks before the clinical presentation. These types of reactions also have been reported with the use of other monoclonal antibodies.